Schizophrenia market to reach $17 billion in 7MM by 2031

The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% from $8.4 billion in 2021 to $17.0 billion in 2031, driven by the anticipated introduction of 11 late-stage pipeline products during the forecast period, according to pharma analytics company GlobalData.

GlobalData’s latest report, “Schizophrenia: Seven-Market Drug Forecast and Market Analysis – Update”, reveals that the late-stage pipeline products are expected to capture a significant portion of the schizophrenia market, accounting for 33.4% of global sales in 2031, despite the atypical antipsychotics retaining the largest portion of patient shares.

“The pipeline products are all expected to have a significantly higher annual cost of therapy (ACOT) when compared with the cheap generic atypical antipsychotics that are predominantly used. Due to the higher ACOT, the pipeline products are unlikely to replace current antipsychotics as first-line treatment options. However, adjunctive therapies that can be used in combination with antipsychotics could be introduced in earlier lines of therapy,” commented Christie Wong, neurology analyst at GlobalData.